The lead developer of the COVID-19 vaccine being developed by the University of Oxford and AstraZeneca, Professor Andrew Pollard, questioned the drug's ability to protect everyone from the coronavirus. RIA Novosti writes about it.
According to him, the results of three of the vaccine candidates planned for procurement by Britain show that they can stop hospitalizations and severe disease. However, it is much more difficult for them to prevent the course of the disease in a mild form. “It is likely that none of the vaccines will protect everyone,” Pollard said, adding that the drugs could reduce the severity of symptoms in those infected with the coronavirus.
Speaking about whether the vaccines being developed are adapted to a possible mutation of the virus, the specialist explained that scientists need more time to adapt drugs to new strains of infection.
AstraZeneca said earlier that an interim analysis of vaccine clinical trials showed an average efficacy of 70 percent. The research also found that protection against COVID-19 appears 14 days after receiving two doses of the vaccine.
